Egrifta (Tesamorelin) Missed-Dose Protocol

The Standard Missed-Dose Rule for Tesamorelin

Skip the missed injection and administer your next 2 mg dose at the regular time the following day. This is the simplest, safest approach, and it aligns with the FDA-approved Egrifta SV prescribing information, which instructs patients not to inject two doses within the same 24-hour period.

The reasoning is pharmacokinetic. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog with a plasma elimination half-life of approximately 26 minutes [1]. After subcutaneous injection, the peptide reaches peak plasma concentration within roughly 0.15 hours, stimulates a burst of endogenous growth hormone (GH) from the anterior pituitary, and is then cleared rapidly. Doubling the dose does not produce a proportionally larger or longer GH pulse. Instead, it risks supratherapeutic IGF-1 elevations without additional visceral fat reduction benefit.

A single skipped dose has minimal clinical impact. The visceral adipose tissue (VAT) reduction seen with tesamorelin develops over weeks to months of consistent daily dosing, not from any individual injection [1]. Think of each injection as one deposit in a long-term account. Missing one deposit does not empty the balance.

Why Tesamorelin's Pharmacology Forgives an Occasional Miss

Tesamorelin works by mimicking the body's own GHRH signal. Each 2 mg injection binds GHRH receptors on anterior pituitary somatotrophs, triggering a GH secretory pulse that peaks within 15 to 45 minutes and returns to baseline within 1 to 3 hours [2]. That GH pulse then drives hepatic IGF-1 production and downstream lipolysis in visceral adipocytes over the following 12 to 18 hours.

This mechanism is pulsatile by design. The healthy pituitary does not secrete GH continuously. It releases GH in bursts, predominantly during sleep and after meals. Tesamorelin adds one additional, pharmacologically timed pulse to that natural rhythm. Skip one pulse, and the pituitary's endogenous GHRH-driven secretion continues uninterrupted. The body does not "zero out."

Contrast this with drugs that require continuous receptor occupancy (antiretrovirals, for example, where a missed dose creates a window for viral replication). Tesamorelin's effect is cumulative and tissue-level, not concentration-dependent at any single timepoint. The Endocrine Society's clinical practice guidelines on GH use note that GH-axis therapies depend on sustained adherence patterns rather than perfect daily compliance [3].

Timing Rules: Same Day vs. Next Day

If you remember your missed dose within a few hours of your usual injection time, you have a decision to make. The prescribing information does not specify a cutoff window, so apply this practical framework:

Remembered within 6 hours of your usual time: You may take the dose. Shift subsequent doses back to your original schedule the next day. Do not inject again within 12 hours.

Remembered more than 6 hours late: Skip the dose. Resume normal timing tomorrow.

This 6-hour threshold is not printed on the label. It is derived from tesamorelin's pharmacodynamic profile: because the drug's meaningful biological effect (the GH pulse and downstream IGF-1 rise) plays out over roughly 12 to 18 hours, injecting within 6 hours preserves enough of a gap before the next scheduled dose to avoid stacking two GH surges too close together. Injecting later than 6 hours compresses that gap to under 12 hours, which increases the likelihood of overlapping IGF-1 peaks without adding clinical benefit.

Your prescriber may give you a different window based on your individual IGF-1 levels and tolerability. Follow their guidance over any general rule.

What Happens if You Miss Multiple Doses

Two consecutive missed doses are unlikely to reverse any visceral fat reduction you have already achieved. The tissue remodeling driven by repeated GH pulses has a slow decay curve. In the Phase III extension study by Falutz et al. (2007), patients who discontinued tesamorelin after 26 weeks saw visceral fat begin to reaccumulate, but the re-gain was gradual, taking months to approach pre-treatment levels [1]. A 2- or 3-day gap is pharmacologically trivial compared to full discontinuation.

Three or more consecutive missed doses warrant a call to your prescriber. Not because the drug is dangerous to restart (it is not), but because a pattern of missed doses may signal an adherence barrier that needs to be addressed. Common barriers include injection-site discomfort, difficulty with reconstitution, or refrigeration logistics during travel.

For planned interruptions (surgery, travel, illness), discuss a temporary hold with your prescriber in advance. Tesamorelin can be stopped and restarted without a titration period. The 2 mg daily dose is both the starting and maintenance dose.

How Tesamorelin Works: Mechanism in Full

Tesamorelin acetate is a synthetic 44-amino-acid peptide identical to human GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that improves enzymatic stability [4]. That modification extends plasma half-life from roughly 7 minutes (native GHRH) to approximately 26 minutes, which is long enough for a single subcutaneous injection to generate a meaningful somatotroph response.

The mechanism proceeds in three stages:

Stage 1 (minutes): Tesamorelin binds the GHRH receptor (GHRHR) on pituitary somatotrophs. Receptor activation increases intracellular cyclic AMP, opening voltage-gated calcium channels and triggering exocytosis of stored GH granules. Plasma GH rises within 10 to 15 minutes and peaks by 30 to 45 minutes.

Stage 2 (hours): The GH pulse stimulates hepatic IGF-1 synthesis. Circulating IGF-1 rises over 2 to 6 hours and mediates many of GH's downstream metabolic effects, including lipolysis. GH also acts directly on adipocytes via the GH receptor, activating hormone-sensitive lipase in visceral fat depots.

Stage 3 (weeks to months): Repeated daily GH pulses shift the balance of visceral adipocyte lipid turnover toward net lipolysis. In the key trial, patients receiving tesamorelin 2 mg daily achieved a mean 15.2% reduction in trunk fat (measured by CT) at 26 weeks compared to 0.6% in the placebo group (N=412, P<0.001) [1]. Limb fat was preserved, a key differentiator from caloric restriction alone.

The specificity for visceral fat appears related to the higher density of GH receptors and hormone-sensitive lipase activity in visceral versus subcutaneous adipocytes. A secondary analysis published in the Journal of Clinical Endocrinology & Metabolism confirmed that tesamorelin reduced VAT by approximately 18% without significant change in subcutaneous adipose tissue [5].

IGF-1 Monitoring and Missed Doses

Your prescriber should check IGF-1 levels at baseline and periodically during treatment. The FDA label recommends discontinuation if IGF-1 exceeds 3.0 times the upper limit of normal (ULN) on repeat testing [4]. An occasional missed dose will not cause a rebound IGF-1 spike. If anything, a gap lowers the IGF-1 trough slightly.

Do not try to "catch up" by injecting extra doses after a miss. The concern is not IGF-1 toxicity from a single double dose but rather the principle that supratherapeutic GH pulsing provides no additional VAT reduction while potentially worsening side effects like arthralgias, peripheral edema, and carpal tunnel symptoms. In the Phase III trial, arthralgias occurred in 13.3% of tesamorelin-treated patients versus 8.5% on placebo [1]. Higher peak GH levels from dose stacking would predictably increase that rate.

Patients with a history of elevated IGF-1 or with active malignancy concerns should be especially careful to avoid any unscheduled additional doses. The Endocrine Society recommends maintaining IGF-1 within the age-adjusted normal range during any GH-axis therapy [3].

Reconstitution, Storage, and Practical Adherence Tips

Egrifta SV (the current formulation) comes as a lyophilized powder requiring reconstitution with the supplied diluent (sterile water for injection). Once reconstituted, the solution should be injected immediately. Do not store reconstituted tesamorelin in the refrigerator for later use [4].

Several practical strategies reduce the chance of a missed dose:

Consistent timing. Pick a time that maps to an existing daily habit. Many patients inject in the morning before breakfast or at bedtime. Morning dosing aligns the exogenous GH pulse with the natural cortisol-driven GH nadir, while bedtime dosing stacks it with the endogenous nocturnal GH surge. Neither timing has been shown to be clinically superior.

Travel preparation. Unreconstituted vials are stable at room temperature (up to 25°C / 77°F) for the duration of their shelf life. Carry vials in a cool bag during air travel but do not freeze them. Pre-plan enough supply for the trip plus 2 extra days.

Injection-site rotation. Rotate between the abdomen (avoiding a 2-inch radius around the navel), anterior thigh, and posterior upper arm. Consistent rotation reduces injection-site reactions (reported in 8.4% of patients in Phase III) and removes a common reason patients skip doses [1].

Set a daily alarm. This is the single most effective adherence intervention across all injectable therapies. A 2019 meta-analysis of self-injection adherence in chronic disease found that daily reminders improved adherence by an absolute 12 to 15 percentage points [6].

Tesamorelin in Context: Why Adherence Matters for Visceral Fat

HIV-associated lipodystrophy is not a cosmetic problem. Excess visceral adipose tissue in people living with HIV correlates independently with increased cardiovascular risk, insulin resistance, and hepatic steatosis. A study published in The Lancet HIV found that people with HIV and lipodystrophy had a 1.4-fold higher risk of cardiovascular events compared to HIV-positive controls without lipodystrophy [7].

Tesamorelin is the only FDA-approved pharmacotherapy for this condition. In the key trial by Falutz et al., tesamorelin 2 mg daily reduced trunk fat by 15.2% at 26 weeks, with secondary improvements in patient-reported body image distress scores (P<0.001 vs. placebo) [1]. Extension data showed that patients who maintained treatment for 52 weeks achieved continued VAT reduction, while those switched to placebo at week 26 experienced gradual re-accumulation [8].

Dr. Julian Falutz, the lead investigator of the key trial, stated: "The visceral fat reduction with tesamorelin is specific and sustained during treatment, but it is not curative. Discontinuation leads to return of adipose accumulation, which underscores the need for long-term adherence" [1].

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity pharmacotherapy recognized that treatment adherence is the primary determinant of sustained efficacy for body-composition therapies, noting that "suboptimal adherence, rather than pharmacologic failure, accounts for most apparent non-response in clinical practice" [9].

When to Contact Your Prescriber About Missed Doses

Call your prescribing clinician if any of the following apply:

You have missed three or more consecutive daily doses. You are experiencing side effects (joint pain, swelling, numbness or tingling in hands) that are causing you to skip doses intentionally. You have difficulty with the reconstitution process. You have upcoming surgery or a medical procedure that may require temporary discontinuation. Your most recent IGF-1 level was above the age-adjusted upper limit of normal, and you are unsure whether to resume after a gap.

Your prescriber may recheck IGF-1 after resumption if the gap exceeded 7 days, though this is a clinical judgment call, not a labeled requirement.

Tesamorelin requires no dose adjustment for renal impairment or hepatic impairment based on available data. It has not been studied in patients under 18 or in pregnant individuals and is contraindicated in pregnancy due to theoretical GH-axis effects on fetal growth [4].